Genetic Predisposition to Advanced Glycation End Products Toxicity Is Related to Prognosis of Chronic Hemodialysis Patients

被引:17
|
作者
Kalousova, Marta [1 ,2 ]
Jachymova, Marie [1 ,2 ]
Germanova, Alexandra [1 ,2 ]
Kubena, Ales Antonin [4 ]
Tesar, Vladimir [3 ]
Zima, Tomas [1 ,2 ]
机构
[1] Charles Univ Prague, Fac Med 1, Inst Clin Biochem, CZ-12111 Prague 2, Czech Republic
[2] Charles Univ Prague, Fac Med 1, Diagnost Lab, CZ-12111 Prague, Czech Republic
[3] Charles Univ Prague, Fac Med 1, Dept Nephrol, CZ-12111 Prague 2, Czech Republic
[4] Charles Univ Prague, Fac Pharm Hradec Kralove, CZ-12111 Prague 2, Czech Republic
来源
KIDNEY & BLOOD PRESSURE RESEARCH | 2010年 / 33卷 / 01期
关键词
Advanced glycation end products; Cardiovascular mortality; Glyoxalase; Hemodialysis; Polymorphisms; Receptor for advanced glycation end products; Soluble receptor for advanced glycation end products; CORONARY-ARTERY-DISEASE; TYPE-2; DIABETES-MELLITUS; STAGE RENAL-DISEASE; RAGE GENE; GLYOXALASE-I; CARDIOVASCULAR-DISEASE; INFLAMMATORY RESPONSE; THE-374A ALLELE; RECEPTOR; POLYMORPHISM;
D O I
10.1159/000285845
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Background: Advanced glycation end products (AGEs) belong to uremic toxins and some pathological effects of AGEs are linked to RAGE (receptor for AGEs). Their precursors are detoxified by the glyoxalase (GLO) system. The A419C (E111A) polymorphism of the GLO I gene is associated with vascular disease in hemodialysis (HD) patients and some RAGE gene polymorphisms are implicated in various pathological states. Aim: To study the relationship of A419C GLO I and four RAGE polymorphisms (-429T/C, -374T/A, 2184A/G and Gly82Ser) in the prognosis of HD patients. Methods: The group studied consisted of 214 chronic HD patients prospectively followed up for 43 months. 100 patients died, 48 due to cardiovascular causes. Results: The Kaplan-Meier analysis showed a higher mortality rate in patient-mutated homozygotes for RAGE -429CC, RAGE 2184GG and GLO I419CC. A higher hazard risk was confirmed by the Cox proportional hazards model when wild-type homozygotes were taken as reference: RAGE -429CC 2.28 (95% CI 1.04-4.99), RAGE 2184GG 3.16 (95% CI 1.44-6.93), and GLO I419CC 1.75 (95% CI 1.08-2.86). Both RAGE polymorphisms were also associated with cardiovascular mortality: RAGE -429CC 3.54 (95% CI 1.37-9.14) and RAGE 2184GG 5.04 (95% CI 1.93-13.11). Conclusion: In summary, our study shows for the first time a link between RAGE and GLO polymorphisms in the prognosis of HD patients. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:30 / 36
页数:7
相关论文
共 50 条
  • [21] Detection of Free Advanced Glycation End Products in Vivo during Hemodialysis
    Hohmann, Christoph
    Liehr, Kristin
    Henning, Christian
    Fiedler, Roman
    Girndt, Matthias
    Gebert, Michael
    Hulko, Michael
    Storr, Markus
    Glomb, Marcus A.
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2017, 65 (04) : 930 - 937
  • [22] Advanced glycation end products and receptor for advanced glycation end products in AA amyloidosis
    Röcken, C
    Kientsch-Engel, R
    Mansfeld, S
    Stix, B
    Stubenrauch, K
    Weigle, B
    Bühling, F
    Schwan, M
    Saeger, W
    AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (04): : 1213 - 1220
  • [23] Advanced glycation and lipoxidation end products: reactive carbonyl compounds-related uraemic toxicity
    Miyata, T
    Saito, A
    Kurokawa, K
    de Strihou, CV
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 : 8 - 11
  • [24] ADVANCED GLYCATION END PRODUCTS (AGES), CARDIOVASCULAR DISEASE AND CKD-MBD IN HEMODIALYSIS PATIENTS
    Nogueira, Luiz C. F.
    Borges, Cynthia M.
    Franca, Renata A.
    Salani, Talita G.
    Barcelos, Viviane M.
    de Oliveira, Rodrigo B.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [25] Erratum: The influence of body mass index on the accumulation of advanced glycation end products in hemodialysis patients
    S Arsov
    L Trajceska
    W van Oeveren
    A J Smit
    P Dzekova
    B Stegmayr
    A Sikole
    G Rakhorst
    R Graaff
    European Journal of Clinical Nutrition, 2015, 69 : 410 - 410
  • [26] Advanced glycation end products was a risk factor of progression of atherosclerosis in the maintenance hemodialysis patients.
    Uchimura, T
    Mortomiya, Y
    Hashiguchi, T
    Iwamoto, H
    Maruyama, I
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 226A - 226A
  • [27] HEPATITIS C HAS NO INFLUENCE ON THE ACCUMULATION OF ADVANCED GLYCATION END-PRODUCTS IN HEMODIALYSIS PATIENTS
    Arsov, S.
    Graaff, R.
    van Oeveren, W.
    Busletic, I.
    Trajcevska, L.
    Selim, G.
    Dzekova, P.
    Sikole, A.
    Rakhorst, G.
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2009, 32 (07): : 442 - 442
  • [28] Serum and Tissue Levels of Advanced Glycation End Products and Risk of Mortality in Patients on Maintenance Hemodialysis
    Jiang, Jianping
    Zhang, Yuanyuan
    Chen, Jianghua
    Yang, Xiaobing
    Mei, Changlin
    Xiong, Fei
    Shi, Wei
    Zhou, Wei
    Liu, Xusheng
    Sun, Shiren
    Zhang, Ping
    Zhang, Yixiang
    Zhang, Yanmin
    Liu, Shuangxin
    Zhang, Zhimin
    Lin, Qizhan
    Yu, Yan
    Tian, Jianwei
    Luo, Weihong
    Qin, Xianhui
    Hou, Fan Fan
    AMERICAN JOURNAL OF NEPHROLOGY, 2021, 52 (01) : 8 - 16
  • [29] Advanced Glycation End Products
    Thomas, Merlin C.
    DIABETES AND THE KIDNEY, 2011, 170 : 66 - 74
  • [30] Advanced glycation end products and advanced oxidation protein products in hemodialyzed patients
    Kalousová, M
    Zima, T
    Tesar, V
    Lachmanová, J
    BLOOD PURIFICATION, 2002, 20 (06) : 531 - 536